Copyright © 1995 by the European Society of Cardiology.
© 1995 The European Society of Cardiology
Emerging technology in stress echocardiography
Echocardiography Laboratory, University of Michigan Hospital Michigan, U.S.A.
Correspondence: William F. Armstrong, MD, University of Michigan Medical Center, Division of Cardiology, 9D Rm. 9800, 1500 E. Medical Center Drive, Ann Arbor, Michigan 48109-0119, U.S.A.
Stress echocardiography has seen substantial expansion as a clinically useful tool for evaluation of patients with chest pain syndromes, determining the physiological significance of coronary artery lesions and assessing prognosis in patients known to have coronary disease. Several newly developing technologies show promise for enhancing the accuracy and clinical applicability of the examination. These include automatic edge detection systems, intravenous contrast for enhanced endocardial definition, tissue Doppler imaging, and tissue characterization techniques. Finally, new methods of cardiovascular stress, including combinations of exercise and pharmacological agents as well as newly developed pharmacological agents, also show promise for enhancing the clinical utility of stress echocardiography.
Key Words: Echocardiography stress echocardiography coronary disease stress testing
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
M. P. Solano and R. B. Goldberg Lipid Management in Type 2 Diabetes Clin. Diabetes, January 1, 2006; 24(1): 27 - 32. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Espinosa-Larranaga, M. Vejar-Jalaf, and R. Medina-Santillan The importance of low serum levels of high-density lipoprotein cholesterol (HDL-C) as a cardiovascular risk factor Diabetes and Vascular Disease Research, October 1, 2005; 2(1_suppl): S1 - S8. [Abstract] [PDF] |
||||
![]() |
R. Gadsby Review: Diabetic dyslipidaemia -- the case for using statins The British Journal of Diabetes & Vascular Disease, November 1, 2003; 3(6): 402 - 407. [Abstract] [PDF] |
||||
![]() |
G. Siegel, C. Abletshauser, M. Malmsten, A. Schmidt, and K. Winkler Reduction of arteriosclerotic nanoplaque formation and size by fluvastatin in a receptor-based biosensor model Cardiovasc Res, June 1, 2003; 58(3): 696 - 705. [Abstract] [Full Text] [PDF] |
||||
![]() |
References Circulation, December 17, 2002; 106(25): 3373 - 3421. [Full Text] |
||||
![]() |
R. C. Pasternak, S. C. Smith Jr, C. N. Bairey-Merz, S. M. Grundy, J. I. Cleeman, and C. Lenfant ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins Stroke, September 1, 2002; 33(9): 2337 - 2341. [Full Text] [PDF] |
||||
![]() |
R. C. Pasternak, S. C. Smith Jr, C. N. Bairey-Merz, S. M. Grundy, J. I. Cleeman, C. Lenfant, and Writing Committee Members: ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins Circulation, August 20, 2002; 106(8): 1024 - 1028. [Full Text] [PDF] |
||||
![]() |
R. C. Pasternak, S. C. Smith Jr, C. N. Bairey-Merz, S. M. Grundy, J. I. Cleeman, and C. Lenfant ACC/AHA/NHLBI clinical advisory on the use and safety of statins J. Am. Coll. Cardiol., August 7, 2002; 40(3): 567 - 572. [Full Text] [PDF] |
||||
![]() |
E. Rizos and D. P Mikhailidis Are high density lipoprotein (HDL) and triglyceride levels relevant in stroke prevention? Cardiovasc Res, November 1, 2001; 52(2): 199 - 207. [Abstract] [Full Text] [PDF] |
||||
![]() |
D.R. Nair, A.S. Wierzbicki, and D.P. Mikhailidis Time to look beyond just lowering the serum concentration of low density lipoprotein - high density lipoprotein levels are also important Perspectives in Public Health, June 1, 2001; 121(2): 98 - 101. [Abstract] [PDF] |
||||
![]() |
I. T. Pyrah, A. Kalinowski, D. Jackson, W. Davies, S. Davis, A. Aldridge, and P. Greaves Toxicologic Lesions Associated with Two Related Inhibitors of Oxidosqualene Cyclase in the Dog and Mouse Toxicol Pathol, February 1, 2001; 29(2): 174 - 179. [Abstract] [PDF] |
||||
![]() |
K. M. Sharobeem, B. P. Madden, R. Millner, L. M. Rolfe, C. A. Seymour, and J. Parker Acute Renal Failure After Cardiopulmonary Bypass: A Possible Association With Drugs of the Fibrate Group Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 2000; 5(1): 33 - 39. [Abstract] [PDF] |
||||
![]() |
P.W. Serruys, D.P. Foley, G. Jackson, H. Bonnier, C. Macaya, M. Vrolix, A. Branzi, J. Shepherd, H. Suryapranata, P.J. de Feyter, et al. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty: Final results of the fluvastatin angiographic restenosis (FLARE) trial Eur. Heart J., January 1, 1999; 20(1): 58 - 69. [Abstract] [PDF] |
||||










